Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Characteristics of COPD patients newly treated with triple inhaled therapies in Japan claims database
jRCT1030210229Recruiting
- Sponsor
- GSK
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate and Breztri Aerosphere in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoints: Age at index date, Calendar year of index date and 10 more. Started Sep 2021; status: recruiting.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatateBreztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT1030210229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030210229.